	US 12,227,563 B2
	Anti-IGF-I receptor humanized antibody
Akira Tanokura, Tokyo (JP); Hirotsugu Kato, Tokyo (JP); Hiroshi Eguchi, Tokyo (JP); Kenichiro Takagi, Tokyo (JP); Satoshi Yamamura, Tokyo (JP); Naoko Namiki, Tokyo (JP); Daisuke Ishikawa, Kikuchi (JP); Hirofumi Higuchi, Kikuchi (JP); Tomoyo Takeo, Kikuchi (JP); and Masayo Ohori, Kikuchi (JP)
Assigned to Teijin Pharma Limited, Tokyo (JP)
Appl. No. 17/299,383
Filed by Teijin Pharma Limited, Tokyo (JP)
PCT Filed Dec. 2, 2019, PCT No. PCT/JP2019/047050 § 371(c)(1), (2) Date Jun. 3, 2021, PCT Pub. No. WO2020/116398, PCT Pub. Date Jun. 11, 2020.
Claims priority of application No. 2018-226669 (JP), filed on Dec. 3, 2018.
Prior Publication US 2022/0033485 A1, Feb. 3, 2022
Int. Cl. A61K 39/00 (2006.01); A61P 3/10 (2006.01); C07K 16/22 (2006.01); C12N 5/077 (2010.01)

CPC C07K 16/22 (2013.01) [A61P 3/10 (2018.01); C12N 5/0658 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01)]

6 Claims

1. An anti-IGF-I receptor humanized antibody or antigen-binding fragment thereof or a derivative thereof comprising:

a heavy-chain variable region comprising the amino acid sequence of SEQ ID NO:7; and

a light-chain variable region comprising an amino acid sequence selected from SEQ ID NOs:8, 9, 10, 11, and 12.